Hagop Kantarjian, MD, on CAR T Cells in Relapsed/Refractory ALL
2014 ASH Annual MeetingHagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 380, “T Cells Engineered with a Chimeric Antigen Receptor (CAR)-Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children With Relapsed, Refractory ALL,” presented by Stephan A. Grupp, MD, PhD; abstract 381, “Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia,” presented by Daniel W. Lee III, MD; and abstract 382, “CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients With Relapsed, Refractory B-Cell ALL,” presented by Jae H. Park, MD.
Related Videos
Linda J. Burns, MD, on CAR T-Cell Therapy in ALL
2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 380,
Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial
Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 146, “
Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 634, “Imetelstat, a Telomerase Inhibitor, T...
Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis
Laurie Sehn, MD, on Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 289, “Nivolumab in Patients With Relapsed...
Sagar Lonial, MD, on Monoclonal Antibodies in Multiple Myeloma
Sagar Lonial, MD, of Winship Cancer Institute, offers his thoughts on abstract 302, “Final Resu...
